Skip to main content


Mikrobiomik is a biopharmaceutical company founded for the research, development, production and commercialization of biologic medicines based on the human microbiome.

At Mikrobiomik we are developing a new generation of biologic medicines based on the human microbiome, focused on serious diseases, currently without therapeutic alternative such as non-alcoholic steatohepatitis.

Our first biologic medicine under investigation, MBK-01, aimed at treating intestinal infection caused by Clostridioides difficile, is in Phase III ongoing and is expected to be launched on the European market in the first half of 2025.


Our current shareholders, in addition to the founding partners, include:

  • Orza, a direct investment entity, belonging to the Elkarkidetza and Geroa pension funds.
  • Seed Capital Bizkaia, a public company attached to the Department of Economic Promotion of the Provincial Council of Bizkaia, which is strongly committed to fostering innovation, social impact and the promotion and regeneration of the entrepreneurial network in Bizkaia.
  • San Ignacio S.L, a “family office” specially oriented to support disruptive projects.



Capital increase €1.1 M

We have confirmed a capital increase worth 1.1 million euros. This milestone is materialized thanks to the exclusive contribution of its current partners, who are determined to fulfill their initial mission: launch their investigational biological medicine, MBK-01, onto the European market.

Since its founding in 2018, Mikrobiomik has raised a significant sum of capital, demonstrating the trust and support of partners, such as Orza and Seed Capital Bizkaia. In addition, 11 other partners, including family offices and founding partners, have believed in the project since its inception.